{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T22:36:11Z","timestamp":1721946971703},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.tracli.2019.07.005","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T11:26:10Z","timestamp":1565004370000},"page":"217-223","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["In myelodysplastic syndrome cases, what should be the level of ferritin which has prognostic value?"],"prefix":"10.1016","volume":"26","author":[{"given":"A.","family":"Senturk Yikilmaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Akinci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015e.M.","family":"Bakanay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130.","family":"Dilek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2019.07.005_bib0180","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMp048266","article-title":"Myelodysplastic syndromes-coping with ineffective hematopoiesis","volume":"352","author":"Cazzola","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2019.07.005_bib0185","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0145-2126(07)70459-9","article-title":"Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes","volume":"31","author":"Malcovati","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.tracli.2019.07.005_bib0190","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/BF03165122","article-title":"The myelodysplastic syndromes: morphology, risk assessment, and clinical management","volume":"76","author":"Bennett","year":"2002","journal-title":"Int J Hematol"},{"key":"10.1016\/j.tracli.2019.07.005_bib0195","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt \u00d8stg\u00e5rd","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tracli.2019.07.005_bib0200","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00508-014-0627-0","article-title":"10th anniversary of the Austrian MDS Platform: aims and ongoing projects","volume":"127","author":"Burgstaller","year":"2015","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.tracli.2019.07.005_bib0205","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/cncr.21860","article-title":"Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life","volume":"106","author":"Balducci L:","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.tracli.2019.07.005_bib0210","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3324\/haematol.2009.011429","article-title":"Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study","volume":"95","author":"Alessandrino","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.tracli.2019.07.005_bib0215","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10554-006-9203-7","article-title":"Myocardial and hepatic T2* magnetic resonance evaluation in ex-thalassemic patients after bone-marrow transplantation","volume":"23","author":"Mavrogeni","year":"2007","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.tracli.2019.07.005_bib0220","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.pcad.2011.07.004","article-title":"Assessment of iron overload with T2* magnetic resonance imaging","volume":"54","author":"Anderson","year":"2011","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.tracli.2019.07.005_bib0225","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.12734","article-title":"Measurement of liver iron concentration by superconducting quantum interference device (SQUID) biomagnetic liver susceptometry validates serum ferritin as prognostic parameter for allogeneic stem cell transplantation","author":"Jacobi","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.tracli.2019.07.005_bib0230","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.thj.6200028","article-title":"Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?","volume":"1","author":"Cortelezzi","year":"2000","journal-title":"Hematol J"},{"key":"10.1016\/j.tracli.2019.07.005_bib0235","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMra1004967","article-title":"Iron overload in human disease","volume":"366","author":"Fleming","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tracli.2019.07.005_bib0240","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1200\/JCO.2005.01.7038","article-title":"Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making","volume":"23","author":"Malcovati","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tracli.2019.07.005_bib0245","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12185-017-2367-1","article-title":"Iron overload in myelodysplastic syndromes (MDS)","volume":"107","author":"Gattermann","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.tracli.2019.07.005_bib0250","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1182\/blood-2006-10-054924","article-title":"Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation","volume":"109","author":"Armand","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2019.07.005_bib0255","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1182\/blood-2009-07-234062","article-title":"Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?","volume":"114","author":"Pullarkat","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2019.07.005_bib0260","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.bbmt.2014.04.024","article-title":"Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis","volume":"20","author":"Armand","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.tracli.2019.07.005_bib0265","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.leukres.2011.07.007","article-title":"Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS","volume":"35","author":"Park","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.tracli.2019.07.005_bib0270","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3904\/kjim.2009.24.4.368","article-title":"Elevation of serum ferritin is associated with the outcome of patients with newly diagnosed multiple myeloma","volume":"24","author":"Song \u041c\u041a","year":"2009","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.tracli.2019.07.005_bib0275","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.bbmt.2008.08.009","article-title":"Elevated ferritin is associated with relapse after autologous hematopoietic stem cell transplantation for lymphoma","volume":"14","author":"Mahindra","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.tracli.2019.07.005_bib0280","first-page":"509","article-title":"Serum ferritin levels in hematologic malignant neoplasms","volume":"104","author":"Patel","year":"1980","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.tracli.2019.07.005_bib0285","doi-asserted-by":"crossref","first-page":"e0179016","DOI":"10.1371\/journal.pone.0179016","article-title":"Role of serum ferritin level on overall survival in patients with myelodysplastic syndromes: results of a meta-analysis of observational studies","volume":"12","author":"Pileggi \u0421","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.tracli.2019.07.005_bib0290","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.transci.2013.04.025","article-title":"Adverse impact of hyperferritinemia and transfusion dependency on treatment success in myelodysplastic syndrome","volume":"48","author":"Cakar \u041c\u041a","year":"2013","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.tracli.2019.07.005_bib0295","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s12185-012-1048-3","article-title":"Prognostic significance of serum ferritin level at diagnosis in myelodysplastic syndrome","volume":"95","author":"Kikuchi","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.tracli.2019.07.005_bib0300","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000345428","article-title":"Serum ferritin is an independent prognostic factor in Chinese with myelodysplastic syndromes classified as IPSS Intermediate-1","volume":"129","author":"Li","year":"2013","journal-title":"Acta Haematol"},{"key":"10.1016\/j.tracli.2019.07.005_bib0305","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/ajh.23303","article-title":"Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes","volume":"87","author":"Mishra","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tracli.2019.07.005_bib0310","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.leukres.2011.07.007","article-title":"Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS","volume":"35","author":"Park","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.tracli.2019.07.005_bib0315","doi-asserted-by":"crossref","first-page":"633","DOI":"10.17219\/acem\/62397","article-title":"Red blood cell transfusion dependency and hyperferritinemia are associated with impaired survival in patients diagnosed with myelodysplastic syndromes: results from the first polish MDS-PALG registry","volume":"25","author":"Waszczuk-Gajda","year":"2016","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.tracli.2019.07.005_bib0320","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.leukres.2014.01.016","article-title":"Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions","volume":"38","author":"Cui","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.tracli.2019.07.005_bib0325","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2010.31.3353","article-title":"Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model","volume":"29","author":"Naqvi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tracli.2019.07.005_bib0330","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00277-008-0483-y","article-title":"Cytogenetic features in myelodysplastic syndromes","volume":"87","author":"Haase","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.tracli.2019.07.005_bib0335","doi-asserted-by":"crossref","first-page":"e2017021","DOI":"10.4084\/mjhid.2017.021","article-title":"Myelodysplastic Syndromes and Iron Chelation Therapy","volume":"9","author":"Angelucci","year":"2017","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.tracli.2019.07.005_bib0340","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.tracli.2019.07.005_bib0345","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2011.044602","article-title":"Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)","volume":"96","author":"Malcovati","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.tracli.2019.07.005_bib0350","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.hoc.2010.02.005","article-title":"Prognostic classification and risk assessment in myelodysplastic syndromes","volume":"24","author":"Cazzola \u041c","year":"2010","journal-title":"Hematol Oncol Clin North Am"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782019303969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782019303969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T19:00:11Z","timestamp":1574708411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1246782019303969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1246782019303969"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2019.07.005","relation":{},"ISSN":["1246-7820"],"issn-type":[{"value":"1246-7820","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In myelodysplastic syndrome cases, what should be the level of ferritin which has prognostic value?","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2019.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}